BSX

#218
Boston Scientific Corporation Common Stock
48.3 3 USD
-2.21%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
48.13
48.63
Range Annuel
48.13
109.49
Changement quotidien
-2.21%
Changement Mensuel
-15.33%
Evolution sur 6 mois
-52.52%
Changement Annuel
-53.76%
Clôture Précédente
49.4 2
Open
48.3 0
Low
48.1 3
High
48.6 3
Volume
11.2 K
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 71.84 B
  • Employee 59 K
  • Founded 1979
  • CEO Michael F. Mahoney
  • Website www.bostonscientific.com
  • Headquarter Delaware, United States
  • FIGI BBG000C0LW92
  • Industry Dispositifs Médicaux
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
26.26
ratio cours/chiffre d'affaires
4.55

Boston Scientific Corporation Common Stock

Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator. Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen. BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.

Nouvelles